Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310.

Article  PubMed  Google Scholar 

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6:2489–501.

CAS  PubMed  PubMed Central  Google Scholar 

Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, et al. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study. Blood Adv. 2023;7:7459–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

Article  CAS  PubMed  Google Scholar 

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse large B cell Lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617–29.

Article  PubMed  PubMed Central  Google Scholar 

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2:945–56.

Article  CAS  PubMed  Google Scholar 

Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O’Neill LA. Bruton’s tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS One. 2013;8:e74103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–4.

Article  PubMed  Google Scholar 

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev. 2017;58:41–50.

Article  CAS  PubMed  Google Scholar 

Li W, Sano R, Apatira M, DeAnda F, Gururaja T, Yang M, et al. Bruton’s tyrosine kinase inhibitors with distinct binding modes reveal differential functional impact on B-cell receptor signaling. Mol Cancer Ther. 2024;23:35–46.

Article  CAS  PubMed  Google Scholar 

Liu J, Chen C, Wang D, Zhang J, Zhang T. Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. Eur J Med Chem. 2021;217:113329.

Article  CAS  PubMed  Google Scholar 

Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148–67.

Article  CAS  PubMed  Google Scholar 

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu XJ, Xu L, Pang XJ, Ying Yuan X, Yu GX, Li YR, et al. Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy. Bioorg Med Chem. 2021;47:116358.

Article  CAS  PubMed  Google Scholar 

Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021;11:79.

Article  PubMed  PubMed Central  Google Scholar 

Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to ibrutinib in B cell malignancies: one size does not fit all. Trends Cancer. 2018;4:197–206.

Article  CAS  PubMed  Google Scholar 

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism. Blood. 2018;131:2047–59.

Article  CAS  PubMed  Google Scholar 

Sun SL, Wu SH, Kang JB, Ma YY, Chen L, Cao P, et al. Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. J Med Chem. 2022;65:7415–37.

Article  CAS  PubMed  Google Scholar 

Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022;386:735–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.

Article  PubMed  Google Scholar 

Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015;35:S199–s223.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021;14:125.

Article  PubMed  PubMed Central  Google Scholar 

De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74.

Article  PubMed  Google Scholar 

Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther. 2021;20:1388–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019;7:224.

Article  PubMed  PubMed Central  Google Scholar 

Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology. 2012;60:313–9.

Article  PubMed  Google Scholar 

Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33:2442–53.

Article  CAS  PubMed  Google Scholar 

Chen SS, Barrientos JC, Ferrer G, King-Richards M, Chen YJ, Ravichandran P, et al. Duvelisib eliminates CLL B cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a xenograft model. Clin Cancer Res. 2023;29:1984–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Liu R, Su X, Pan Y, Han X, Shao C, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019;18:177.

Article  PubMed  PubMed Central